INFLECTIS BIOSCIENCE

IFB-088 Shows Promise in Phase 2 Trial for Bulbar-Onset ALS, Demonstrating Slower Disease Progression

3 months ago

• Phase 2 clinical trial demonstrates IFB-088 (icerguastat) meets primary safety endpoint and shows significant reduction in disease progression for bulbar-onset ALS patients. • Treated patients in the per protocol population showed notably slower decline, losing 0.95 points monthly on ALSFRS-R compared to 1.42 points in the placebo group. • Biomarker data confirms IFB-088's mechanism of action through integrated stress response activation and oxidative stress reduction, supporting further development.

MIROCALS Trial Results: Low-Dose IL-2 Shows Potential Benefit for Subset of MND Patients

2 years ago

• The MIROCALS trial testing low-dose interleukin-2 (IL-2) for motor neurone disease (MND) failed to meet its primary endpoint for the overall population, with results published in The Lancet on May 9, 2025. • Post-hoc analysis revealed a potential benefit for patients with slower disease progression, identified by low neurofilament levels, showing 18% higher survival rates and 23% decreased functional decline compared to placebo. • The UK MND Clinical Studies Group is currently evaluating the complex findings to determine next steps, with three MND organizations collaborating to expedite access to proven treatments.